ClinicalTrials.gg
CompletedNCT00991107Updated Mar 9, 2011

A Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production

A Phase 1 interventional study of HE3286 in Insulin Resistance, sponsored by Harbor Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-03-09.

Sponsored by Harbor Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,118 studies in Insulin Resistance with a site in United States — 117 open to participants now, 150 under way, 2 of them phase 3. Insulin Resistance · United States.

Enrollment
869th of 936
5 · median 37
Started
2009
with 68 others
Phase 1
116 of 1,118
14 open now
Registered
364th of 1,118
by date

Among the 1,118 studies in Insulin Resistance with a site in United States, this one is the 869th largest by enrollment of the 936 interventional ones that give a count, is one of 69 that started in 2009, is one of 116 in phase 1, and was the 364th registered.

Insulin Resistance

2,972 studies on the registry are indexed under Insulin Resistance; 337 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

117 of the 1,118 studies in Insulin Resistance with a site in United States are open now. Recruiting first, the newest first:

112 more — sign in →

All 117 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 244 Insulin Resistance studies recruiting now, 54 (22%) set no upper age limit and 158 (65%) stop at 75 or younger; 30 take children under 18; 113 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,118 studies in Insulin Resistance with a site in United States, or all of them as a file.
02

Study summary

The objectives of this study are to evaluate the safety and tolerance of 20 mg (10 mg BID) of HE3286 when administered orally over 28 days to obese insulin-resistant adult subjects and, to assess the activity of HE3286 on insulin sensitivity and hepatic glucose production in obese insulin-resistant adult subjects.

Read the detailed description

Hollis-Eden Pharmaceuticals, Inc. is developing a new class of therapeutics for the treatment of Type 2 diabetes mellitus (T2DM). The investigational drug, HE3286, is a synthetic analog of a naturally occurring hormone with a potentially new mechanism of action that may improve the current therapeutic options available to a T2DM patient.

The glucose clamp is the gold standard for measurement of insulin sensitivity. Given the observed activity of HE3286 in reducing insulin resistance in both impaired glucose intolerant subjects and type 2 diabetic patients, it is necessary to evaluate the physiological site of action (i.e. liver vs. skeletal muscle) of HE3286 in order to further understand the mechanism of action and to design future clinical trials.

03

Conditions studied

  • Insulin Resistance

Keywords

  • phase I
  • safety
  • tolerance
  • insulin resistance
  • obese
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject 18-65 years of age
  • (BMI) is at least 29 kg/m2 but no more than 35 kg/m2 for females and no more than 37 kg/m2 for males
  • Subject has fasting blood glucose level of \< 126 mg/dL at Screening
  • Subject has a 2 hour postprandial (following 75 grams glucose administration) blood glucose of 140-200 mg/dL at Screening
  • Subject has fasting plasma insulin >=10 μU/mL

Exclusion criteria

Exclusion Criteria:

  • Subject has a history of cardiovascular disease (including coronary artery disease), clinically significant hepatic, respiratory or renal abnormalities, clinically significant endocrine disorders (including history of diabetes); or clinically significant neurological or psychiatric condition;
  • Subject has any clinically significant abnormalities in laboratory results at screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    HE3286

    HE3286 20 mg (10 mg BID)

    Drug: HE3286

Interventions

  • DrugHE3286

    HE3286 20 mg (10 mg BID) for 28 days

    Also known as: TRIOLEX

06

What researchers measure

Primary outcomes

  1. Safety and tolerance of 20 mg (10 mg BID) of HE3286 when administered orally over 28 days to obese insulin-resistant adult subjects

    Time frame: Study duration and 1-month follow-up

Secondary outcomes

  1. Activity of HE3286 on insulin sensitivity and hepatic glucose production in obese insulin-resistant adult subjects.

    Time frame: Study period (28-days)

07

Study locations

1 site
  • Clinical Site
    Baton Rouge, Louisiana 70808, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Aug 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2009
First posted
Oct 7, 2009
Start
Sep 2009
Primary completionActual
Aug 2010
CompletionActual
Aug 2010
Last update
Mar 9, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00991107
Lead sponsor
Harbor Therapeutics
First posted
Oct 7, 2009
Start date
Sep 2009
Primary completion
Aug 2010
Completion
Aug 2010
Last update
Mar 9, 2011

Study contacts

Dwight R. Stickney, MD
study director · Harbor Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bezisterim

Start the discussion